Limited β2-adrenoceptor haplotypes display different agonist mediated airway responses in asthmatics
2006

Impact of β2-Adrenoceptor Haplotype on Asthma Treatment Responses

Sample size: 45 publication Evidence: moderate

Author Information

Author(s): Anneke van Veen, Eddy A Wierenga, Robert Westland, Frank R Weller, Guus AM Hart, Henk M Jansen, René E Jonkers

Primary Institution: Academic Medical Centre, University of Amsterdam

Hypothesis

The study aimed to evaluate the impact of β2-adrenoceptor haplotypes on β2-agonist mediated airway responses and the development of tolerance in mild to moderate asthmatics.

Conclusion

Differences exist between β2-adrenoceptor genotypes in airway responses and tolerance development, but these differences are unlikely to be clinically significant.

Supporting Evidence

  • Three limited allelic haplotypes were identified among the patients.
  • Statistically significant differences in PD20 methacholine responses were observed based on genotype.
  • Terbutaline pre-treatment significantly reduced PD20 compared to placebo.

Takeaway

The study looked at how different genetic types affect asthma treatment responses, finding some differences, but they probably don't matter much in real life.

Methodology

Patients were genotyped and underwent a double-blind, randomized, cross-over study with terbutaline or placebo, measuring responses to fenoterol and methacholine.

Limitations

The study used a small sample size and focused on short-acting β2-agonists, which may limit the generalizability of the findings.

Participant Demographics

45 asthmatic patients (11 male, 34 female) with a mean FEV1 of 84.6% predicted.

Statistical Information

P-Value

0.0029

Confidence Interval

31–68%

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1465-9921-7-19

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication